These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17141970)

  • 1. Antibody based target tailored antimicrobial chemotherapy - a new approach.
    Singla M
    Med Hypotheses; 2007; 68(5):957-9. PubMed ID: 17141970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of antibodies in the treatment of infectious diseases.
    Chan CE; Chan AH; Hanson BJ; Ooi EE
    Singapore Med J; 2009 Jul; 50(7):663-72; quiz 673. PubMed ID: 19644620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolution of antibodies into versatile tumor-targeting agents.
    Lin MZ; Teitell MA; Schiller GJ
    Clin Cancer Res; 2005 Jan; 11(1):129-38. PubMed ID: 15671537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-based immunotherapy in high-risk neuroblastoma.
    Johnson E; Dean SM; Sondel PM
    Expert Rev Mol Med; 2007 Dec; 9(34):1-21. PubMed ID: 18081947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies for targeted cancer therapy -- technical aspects and clinical perspectives.
    Zangemeister-Wittke U
    Pathobiology; 2005; 72(6):279-86. PubMed ID: 16582579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases.
    Dadachova E; Casadevall A
    Expert Opin Drug Deliv; 2005 Nov; 2(6):1075-84. PubMed ID: 16296810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The case for pathogen-specific therapy.
    Casadevall A
    Expert Opin Pharmacother; 2009 Aug; 10(11):1699-703. PubMed ID: 19558338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts.
    Ostermann E; Garin-Chesa P; Heider KH; Kalat M; Lamche H; Puri C; Kerjaschki D; Rettig WJ; Adolf GR
    Clin Cancer Res; 2008 Jul; 14(14):4584-92. PubMed ID: 18628473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial immunotherapies for infectious diseases.
    Hengel H; Masihi KN
    Int Immunopharmacol; 2003 Aug; 3(8):1159-67. PubMed ID: 12860171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal immunotherapy and immunomodulation: a double-hitter approach to deal with invasive fungal infections.
    Hamad M
    Scand J Immunol; 2008 Jun; 67(6):533-43. PubMed ID: 18397201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cell membrane modification technique using domain 4 of intermedilysin for immunotherapy against cancer.
    Nagamune H; Ohkura K; Umezu K; Shouji H; Kourai H
    Anticancer Res; 2004; 24(5C):3367-72. PubMed ID: 15515433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
    Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
    Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fullerene (C60) immunoconjugates: interaction of water-soluble C60 derivatives with the murine anti-gp240 melanoma antibody.
    Ashcroft JM; Tsyboulski DA; Hartman KB; Zakharian TY; Marks JW; Weisman RB; Rosenblum MG; Wilson LJ
    Chem Commun (Camb); 2006 Jul; (28):3004-6. PubMed ID: 16832518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting virulence: a new paradigm for antimicrobial therapy.
    Clatworthy AE; Pierson E; Hung DT
    Nat Chem Biol; 2007 Sep; 3(9):541-8. PubMed ID: 17710100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
    Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
    Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant polyclonal antibodies: the next generation of antibody therapeutics?
    Haurum JS
    Drug Discov Today; 2006 Jul; 11(13-14):655-60. PubMed ID: 16793535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial drugs that target human--not microbial--genotypes or phenotypes: a paradigm change in human evolutionary response to pathogen selection pressure.
    Apte SP; Apte PP
    Med Hypotheses; 2006; 67(2):359-61. PubMed ID: 16542785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges in monoclonal antibody-based therapies.
    Samaranayake H; Wirth T; Schenkwein D; Räty JK; Ylä-Herttuala S
    Ann Med; 2009; 41(5):322-31. PubMed ID: 19234897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.